Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components-Reference-Cited by-同舟云学术

Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components

Published:2021-01 Issue:1 Volume:48 Page:551-562
ISSN:0301-4851
Container-title:Molecular Biology Reports
language:en
Short-container-title:Mol Biol Rep

Author:

Afaloniati Hara,Poutahidis Theofilos,Giakoustidis Alexander,Gargavanis Athanasios,Giakoustidis Dimitrios,Angelopoulou Katerina^ORCID

Funder

ELPEN Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11033-020-06089-9.pdf

Reference50 articles.

1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

2. Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380. https://doi.org/10.1002/hep.29086

3. Vogel A, Cervantes A, Chau I et al (2019) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Incidence and epidemiology. Ann Oncol. https://doi.org/10.1093/annonc/mdy308

4. Craig AJ, von Felden J, Garcia-Lezana T et al (2020) Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 17:139–152

5. Yang JD, Hainaut P, Gores GJ et al (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589–604

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin;Biomedicine & Pharmacotherapy;2023-08

2. HDAC11, an emerging therapeutic target for metabolic disorders;Frontiers in Endocrinology;2022-10-20

3. Low-power therapeutic lasers on mRNA levels;Lasers in Medical Science;2022-03-14